<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03347097</url>
  </required_header>
  <id_info>
    <org_study_id>KY2017-241</org_study_id>
    <nct_id>NCT03347097</nct_id>
  </id_info>
  <brief_title>Adoptive Cell Therapy of Autologous TIL and PD1-TIL Cells for Patients With Glioblastoma Multiforme</brief_title>
  <official_title>The Safety and Efficacy Study of Autologous Tumor-infiltrating T Lymphocyte（TIL）and Transgenic Modified TIL Cells Adoptive Therapies for Patients With Glioblastoma Multiforme</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huashan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Cell Therapy Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Huashan Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      At present, the investigators want to evaluate safety and efficacy of cell therapy based on
      Tumor-infiltrating T Lymphocyte (TIL）in glioblastoma. Here, we also constructed a transgenic
      modified TIL cells, stablely express a high-level full-length PD1 antibody (PD1-TIL cells),
      which can transduce signals to activate T cells and result in tumor killing. In this study,
      we design two group patients treated with TIL cells and PD1-TIL cells respectively to
      determine the safety and efficacy of autologous TILs or genetically modified TILs in patients
      with glioblastoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Adverse Events related to TIL and PD1-TIL cells infusion</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment Responses Rate</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival Rate</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival Rate</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Glioblastoma Multiforme</condition>
  <arm_group>
    <arm_group_label>TIL cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 days after the end of concurrent chemoradiotherapy，the 300ml TIL cells ( TIL saline + 0.25% human serum albumin) was injected intravenously 2 times every 30 days .</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PD1-TIL cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 days after the end of concurrent chemoradiotherapy，the 300ml PD1-TIL cells ( PD1-TIL saline + 0.25% human serum albumin) was injected intravenously 2 times every 30 days .</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TIL</intervention_name>
    <arm_group_label>TIL cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PD1-TIL</intervention_name>
    <arm_group_label>PD1-TIL cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with histologically confirmed brain glioblastoma multiforme.

          2. Patients with maximum safe resection of the tumor (≥95%) confirmed with contrast MR
             within 72 hours after surgery.

          3. Age from 18 to 70 years.

          4. Karnofsky performance score ≥ 60.

          5. Adequate organ function within 14 days of study registration including the following:
             Adequate bone marrow reserve: absolute neutrophil (segmented and bands) count, (ANC) ≥
             1.0×10^9/L, platelets ≥100×10^9/L; hemoglobin ≥ 9 g/dL. Hepatic: bilirubin ≤1.3 mg/dL
             or 0-22 mmol/L, aspartate transaminase (AST) and alanine transaminase (ALT) &lt; 3×upper
             limit of normal (ULN). Renal: Normal serum Creatinine for age (below) or creatinine
             clearance &gt;60 ml/min/1.73 m2. Electrocardiogram: normal.

          6. Written informed consent must be obtained from all patients.

        Exclusion Criteria:

          1. Pregnant or breast-feeding patients. Pregnancy testing will be performed on all
             menstruating females within 14 days of study enrollment.

             Patients with uncontrolled intercurrent illness including, but not limited to ongoing
             or active infection, symptomatic congestive heart failure, unstable angina pectoris,
             or psychiatric illness/social situations that would limit compliance with study
             requirements.

          2. Patients with history of immune system abnormalities such as hyperimmunity (e.g.,
             autoimmune diseases) and hypoimmunity (e.g., myelodysplastic disorders, marrow
             failures, AIDS, ongoing pregnancy, transplant immuno-suppression), or medication of
             cortisol.

          3. Patients with any conditions that could potentially alter immune function (e.g., AIDS,
             multiple sclerosis, diabetes, renal failure).

        Patients currently received any other investigational agents.

        -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>liang zhou, dr</last_name>
    <email>lfzhouc@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>jun qian, dr</last_name>
    <email>qianqj@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Huashan hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yu Yao, MD, PhD</last_name>
      <email>yu_yao03@126.com</email>
    </contact>
    <contact_backup>
      <last_name>chao tang, MD</last_name>
      <email>tangchao12345678@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>November 2, 2017</study_first_submitted>
  <study_first_submitted_qc>November 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2017</study_first_posted>
  <last_update_submitted>December 7, 2019</last_update_submitted>
  <last_update_submitted_qc>December 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Huashan Hospital</investigator_affiliation>
    <investigator_full_name>Xiaojie Ding</investigator_full_name>
    <investigator_title>Resident</investigator_title>
  </responsible_party>
  <keyword>glioma</keyword>
  <keyword>TIL</keyword>
  <keyword>PD1-TIL</keyword>
  <keyword>immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

